Nataliia Zaverukha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Nataliia Zaverukha has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- A. S. Musiienko
State Institution “D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
8 shared publications - Nataliia Grygorieva
State Institution “D.F. Chebotarev Institute of Gerontology of the National Academy of Medical Sciences of Ukraine”, Kyiv, Ukraine
7 shared publications - Vladyslav Povoroznyuk
State Institution “D.F. Chebotarev Institute of Gerontology of the NAMS of Ukraine”, Kyiv, Ukraine
7 shared publications - Maryna Bystrytska
State Institution “D.F. Chebotarev Institute of Gerontology of the NAMS of Ukraine”, Kyiv, Ukraine
5 shared publications - Tetiana Solonenko
D.F. Chebotarev Institute of Gerontology of the NAMS of Ukraine, Kyiv, Ukraine
4 shared publications A.A. Tkachuk
State Institution “D.F. Chebotarev Institute of Gerontology of the NAMS of Ukraine”, Kyiv, Ukraine
2 shared publications
Latest Publications
- Open Access
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 845-851
Development of an equation for estimating body fat mass using basic demographic and anthropometric indices
Background. Alongside classical obesity, sarcopenic obesity (SO), a complex condition characterized by a simultaneous increase in fat mass (FM) and a decrease in skeletal muscle strength and mass, is being increasingly diagnosed. Determining FM is crucial in the diagnosis of SO; however, reference methods such as dual-energy X-ray absorptiometry (DXA) are not always accessible in clinical practice. There is a need for simple and accessible screening methods to detect increased FM. The purpose was to develop and validate equation for estimating FM using basic demographic and anthropometric indicators for the Ukrainian population, in order to improve the effectiveness of SO diagnosis. Materials and methods. A retrospective study analyzed data from 374 women aged 50 years and older who were divided into two groups: experimental (n = 269) and validation (n = 105). FM was measured using DXA (Discovery Wi, Hologic, Inc., USA). Stepwise multiple linear regression was used to develop equations for FM estimation, with FM as the dependent variable and anthropometric (height, body weight, waist and hip circumference) and demographic variables as independent predictors. Results. The resulting equation is as follows: FMc (kg) = 0.649 × body weight (kg) – 0.183 × height (cm) – 0.068 × waist circumference (cm) + 0.125 × hip circumference (cm) + 4.0 (coefficient of determination = 0.92, standard error of estimate = 2.9 kg). Conclusions. The proposed equation to evaluate FM using anthropometric and demographic variables demonstrated diagnostic accuracy comparable to the reference DXA method. This makes it a potentially useful tool for clinical practice, particularly in primary care settings or in cases where access to DXA is limited.
- 30 December 2025
- Published by Publishing House Zaslavsky in INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine)
- Vol. 21 (8) , 845-851
Open AccessDevelopment of an equation for estimating body fat mass using basic demographic and anthropometric indices
Background. Alongside classical obesity, sarcopenic obesity (SO), a complex condition characterized by a simultaneous increase in fat mass (FM) and a decrease in skeletal muscle strength and mass, is being increasingly diagnosed. Determining FM is crucial in the diagnosis of SO; however, reference methods such as dual-energy X-ray absorptiometry (DXA) are not always accessible in clinical practice. There is a need for simple and accessible screening methods to detect increased FM. The purpose was to develop and validate equation for estimating FM using basic demographic and anthropometric indicators for the Ukrainian population, in order to improve the effectiveness of SO diagnosis. Materials and methods. A retrospective study analyzed data from 374 women aged 50 years and older who were divided into two groups: experimental (n = 269) and validation (n = 105). FM was measured using DXA (Discovery Wi, Hologic, Inc., USA). Stepwise multiple linear regression was used to develop equations for FM estimation, with FM as the dependent variable and anthropometric (height, body weight, waist and hip circumference) and demographic variables as independent predictors. Results. The resulting equation is as follows: FMc (kg) = 0.649 × body weight (kg) – 0.183 × height (cm) – 0.068 × waist circumference (cm) + 0.125 × hip circumference (cm) + 4.0 (coefficient of determination = 0.92, standard error of estimate = 2.9 kg). Conclusions. The proposed equation to evaluate FM using anthropometric and demographic variables demonstrated diagnostic accuracy comparable to the reference DXA method. This makes it a potentially useful tool for clinical practice, particularly in primary care settings or in cases where access to DXA is limited.
- Open Access
- 29 June 2025
- Published by Orthopaedica, Traumatology, and Prosthetics in ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS
- No. 2
OSTEOARTHRITIS AND GERIATRIC SYNDROMES: FEATURES OF THE RELATIONSHIP AND MANAGEMENT OPPORTUNITIES (LITERATURE REVIEW)
Osteoarthritis (OA) is one of the leading age-associated musculoskeletal isorders, the prevalence of which is increasing due to population aging. The aim of this study is to analyze current literature data regarding the relation and management possibilities of OA and common geriatric syndromes. Methods. A systematic literature review was conducted using analytical methods across scientific databases such as PubMed, Web of Science, Scopus, and Google Scholar for the period 2019–2024. The search was performed using the keywords: “osteoarthritis,” “sarcopenia,” “sarcopenic obesity,” “dysmobility,” “malnutrition,” and “undernutrition.” Results. Typical geriatric syndromes (sarcopenia, sarcopenic obesity, dysmobility syndrome, and malnutrition) are the common phenomenons among OA patients. These conditions share common pathophysiological mechanisms that mutually aggravate each other’s course. The analysis of current literature revealed a lack of comprehensive studies on the combination of OA with geriatric syndromes, especially in the Ukrainian scientific space. This article provides an overview and analysis of current scientific data regarding prevalence, risk factors, pathophysiological mechanisms, diagnostic features, clinical manifestations, as well as potential approaches to treatment, prevention, and rehabilitation of patients with OA in combination with the most common geriatric syndromes. Conclusions. The literature analysis demonstrated bidirectional interaction mechanisms between OA and other geriatric syndromes, highlighting the importance of developing effective strategies for early detection, prevention, and management of such patients within a multidisciplinary approach.
- 29 June 2025
- Published by Orthopaedica, Traumatology, and Prosthetics in ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS
- No. 2
Open AccessOSTEOARTHRITIS AND GERIATRIC SYNDROMES: FEATURES OF THE RELATIONSHIP AND MANAGEMENT OPPORTUNITIES (LITERATURE REVIEW)
Osteoarthritis (OA) is one of the leading age-associated musculoskeletal isorders, the prevalence of which is increasing due to population aging. The aim of this study is to analyze current literature data regarding the relation and management possibilities of OA and common geriatric syndromes. Methods. A systematic literature review was conducted using analytical methods across scientific databases such as PubMed, Web of Science, Scopus, and Google Scholar for the period 2019–2024. The search was performed using the keywords: “osteoarthritis,” “sarcopenia,” “sarcopenic obesity,” “dysmobility,” “malnutrition,” and “undernutrition.” Results. Typical geriatric syndromes (sarcopenia, sarcopenic obesity, dysmobility syndrome, and malnutrition) are the common phenomenons among OA patients. These conditions share common pathophysiological mechanisms that mutually aggravate each other’s course. The analysis of current literature revealed a lack of comprehensive studies on the combination of OA with geriatric syndromes, especially in the Ukrainian scientific space. This article provides an overview and analysis of current scientific data regarding prevalence, risk factors, pathophysiological mechanisms, diagnostic features, clinical manifestations, as well as potential approaches to treatment, prevention, and rehabilitation of patients with OA in combination with the most common geriatric syndromes. Conclusions. The literature analysis demonstrated bidirectional interaction mechanisms between OA and other geriatric syndromes, highlighting the importance of developing effective strategies for early detection, prevention, and management of such patients within a multidisciplinary approach.
- Open Access
- 30 June 2024
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 14 (2) , 69-75
Age-associated risk of sarcopenia, falls and fractures: results of Ukrainian cohort study
Background. It is well-known that sarcopenia increases the risk of falls and fractures, and therefore, requires correction to improve the quality of life of elderly people. This research purposed to study the age-related changes in the sarcopenia risk, falls, and fractures in Ukrainian women in the late reproductive and postmenopausal periods. Materials and methods. We examined 573 females aged from 40 to 89 years old. The subjects were grouped by age decades and presence of high sarcopenia risk (HSR). The SARC-F questionnaire measured the sarcopenia risk, and the risk of falls using the Desmond Fall Risk Questionnaire, the 10-year probability of major osteoporotic and hip fractures was assessed by FRAX, and daily activity — according to the IADL scale. Also, we performed the hand grip strength and five-repetition sit-to-stand tests. Results. The frequency of HSR increased with age from 1.5 % in the 40–49-year-old group to 73.7 % in subjects over 80, as well as fracture and fall risks (p < 0.00001 for both indices) related to decreasing independence in the subject’s everyday life. Also, we revealed age-dependent loss of muscle strength according to the hand grip and the five-repetition sit-to-stand tests. After the adjustment of the subjects by age we found that the females with HSR had a higher risk of falls, a lower level of independence, and increased frequency and risk of osteoporotic fractures. Conclusions. Women with HSR have a higher risk of falls, fractures, and more limitations in daily living activities independently from age and body mass index. These findings request comprehensive management of older women with attention to various parameters for the increase of independence and quality of life.
- 30 June 2024
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 14 (2) , 69-75
Open AccessAge-associated risk of sarcopenia, falls and fractures: results of Ukrainian cohort study
Background. It is well-known that sarcopenia increases the risk of falls and fractures, and therefore, requires correction to improve the quality of life of elderly people. This research purposed to study the age-related changes in the sarcopenia risk, falls, and fractures in Ukrainian women in the late reproductive and postmenopausal periods. Materials and methods. We examined 573 females aged from 40 to 89 years old. The subjects were grouped by age decades and presence of high sarcopenia risk (HSR). The SARC-F questionnaire measured the sarcopenia risk, and the risk of falls using the Desmond Fall Risk Questionnaire, the 10-year probability of major osteoporotic and hip fractures was assessed by FRAX, and daily activity — according to the IADL scale. Also, we performed the hand grip strength and five-repetition sit-to-stand tests. Results. The frequency of HSR increased with age from 1.5 % in the 40–49-year-old group to 73.7 % in subjects over 80, as well as fracture and fall risks (p < 0.00001 for both indices) related to decreasing independence in the subject’s everyday life. Also, we revealed age-dependent loss of muscle strength according to the hand grip and the five-repetition sit-to-stand tests. After the adjustment of the subjects by age we found that the females with HSR had a higher risk of falls, a lower level of independence, and increased frequency and risk of osteoporotic fractures. Conclusions. Women with HSR have a higher risk of falls, fractures, and more limitations in daily living activities independently from age and body mass index. These findings request comprehensive management of older women with attention to various parameters for the increase of independence and quality of life.
- Open Access
- 26 January 2024
- Published by Research Institute of Biology of the V.N. Karazin Kharkiv National University, Ukraine in Ageing and Longevity
- Vol. 5 (1 2024) , 1-9
Risk of sarcopenia in subjects with osteoporosis and osteoarthritis
The study aimed to determine the relationship between the risk of sarcopenia (SP) and common age-related diseases of the musculoskeletal system, such as osteoporosis (OP) and osteoarthritis (OA). There were examined 460 women aged 50-85 years (mean age 66.4 ± 8.8 years) and they were divided into 4 groups. Group I included 176 women without bone and joint diseases (BJD); Group II included 137 persons with a diagnosis of systemic OP; Group III included 95 subjects with knee and/or hip OA (2nd-3rd degree of Kellgren-Lawrence grades); IV group included 52 females with OP and large joints OA (2nd-3rd degree of Kellgren-Lawrence grades). Bone mineral density (BMD) and trabecular bone score (TBS) were determined in all patients using dual-energy X-ray absorptiometry (DXA), which was subsequently taken into account in the calculation of the 10-year probability of the major osteoporotic fractures according to the Ukrainian version of FRAX®. The following questionnaires were used: SARC-F, IADL, Desmond Fall Risk Questionnaire, and KOOS-12. Also, we used the chair stand test (5 times sit-to-stand) and hand grip dynamometer test. The frequency of persons with risk of SP in Group I was 20.3 %, and it was significantly higher in women with OP (33.5 %, χ2= 6.9 [3.4 – 23.0], p < 0.05), subjects with OA (34.7 %, χ2= 6.7 [3.4 – 25.7], p < 0.05), and women with combined pathology (44.2 %, χ2= 12.1 [9.8 – 38.2], p < 0.05). In patients with OA and risk of SP, pain intensity was significantly higher (43.7 [31.3 – 62.5] points compared to patients with OA without risk of SP - 68.8 [50.0 – 93.8] points, Z = 3.6, p < 0.05), as well as function, and daily living (43.8 [31.3 – 68.8] and 75.0 [56.3 – 100.0] points, respectively, Z = 4.1, p < 0.05 and quality of life 43.8 [37.5 – 62.8] and 75.0 [43.8 – 87.5] points, respectively (Z = 3.0, p < 0.05) according to the KOOS-12. The probability of the major OP fracture was significantly higher in the group of OP and risk of SP (11.0 [8.5 – 12.0] % compared to patients with OP without risk of SP - 8.1 [5.4 – 10.0] %, Z = - 3.8, p < 0.05). The same differences were found for the 10-year probability of hip fracture (5.0 [2.8 – 7.3] and 2.1 [1.5 – 3.5] %, respectively, Z = - 4.9, p < 0.05). High Risk of SP, falls and the need for external assistance were recorded significantly more often in women with OP pathology, and their skeletal muscle strength was significantly lower. Women with a high risk of SP had significantly lower skeletal muscle strength (according to hand grip dynamometry), a higher risk of falls and fractures, and a greater need for assistance. The combination of a risk of SP and OA was associated with more severe joint pain intensity, lower function, and quality of life, and the risk of SP and OP combination was associated with a higher risk of OP fracture. _________________________________________________________________________________________ Keywords: sarcopenia; osteoporosis; osteoarthritis; FRAX; fracture; fall; pain; quality of life.
- 26 January 2024
- Published by Research Institute of Biology of the V.N. Karazin Kharkiv National University, Ukraine in Ageing and Longevity
- Vol. 5 (1 2024) , 1-9
Open AccessRisk of sarcopenia in subjects with osteoporosis and osteoarthritis
The study aimed to determine the relationship between the risk of sarcopenia (SP) and common age-related diseases of the musculoskeletal system, such as osteoporosis (OP) and osteoarthritis (OA). There were examined 460 women aged 50-85 years (mean age 66.4 ± 8.8 years) and they were divided into 4 groups. Group I included 176 women without bone and joint diseases (BJD); Group II included 137 persons with a diagnosis of systemic OP; Group III included 95 subjects with knee and/or hip OA (2nd-3rd degree of Kellgren-Lawrence grades); IV group included 52 females with OP and large joints OA (2nd-3rd degree of Kellgren-Lawrence grades). Bone mineral density (BMD) and trabecular bone score (TBS) were determined in all patients using dual-energy X-ray absorptiometry (DXA), which was subsequently taken into account in the calculation of the 10-year probability of the major osteoporotic fractures according to the Ukrainian version of FRAX®. The following questionnaires were used: SARC-F, IADL, Desmond Fall Risk Questionnaire, and KOOS-12. Also, we used the chair stand test (5 times sit-to-stand) and hand grip dynamometer test. The frequency of persons with risk of SP in Group I was 20.3 %, and it was significantly higher in women with OP (33.5 %, χ2= 6.9 [3.4 – 23.0], p < 0.05), subjects with OA (34.7 %, χ2= 6.7 [3.4 – 25.7], p < 0.05), and women with combined pathology (44.2 %, χ2= 12.1 [9.8 – 38.2], p < 0.05). In patients with OA and risk of SP, pain intensity was significantly higher (43.7 [31.3 – 62.5] points compared to patients with OA without risk of SP - 68.8 [50.0 – 93.8] points, Z = 3.6, p < 0.05), as well as function, and daily living (43.8 [31.3 – 68.8] and 75.0 [56.3 – 100.0] points, respectively, Z = 4.1, p < 0.05 and quality of life 43.8 [37.5 – 62.8] and 75.0 [43.8 – 87.5] points, respectively (Z = 3.0, p < 0.05) according to the KOOS-12. The probability of the major OP fracture was significantly higher in the group of OP and risk of SP (11.0 [8.5 – 12.0] % compared to patients with OP without risk of SP - 8.1 [5.4 – 10.0] %, Z = - 3.8, p < 0.05). The same differences were found for the 10-year probability of hip fracture (5.0 [2.8 – 7.3] and 2.1 [1.5 – 3.5] %, respectively, Z = - 4.9, p < 0.05). High Risk of SP, falls and the need for external assistance were recorded significantly more often in women with OP pathology, and their skeletal muscle strength was significantly lower. Women with a high risk of SP had significantly lower skeletal muscle strength (according to hand grip dynamometry), a higher risk of falls and fractures, and a greater need for assistance. The combination of a risk of SP and OA was associated with more severe joint pain intensity, lower function, and quality of life, and the risk of SP and OP combination was associated with a higher risk of OP fracture. _________________________________________________________________________________________ Keywords: sarcopenia; osteoporosis; osteoarthritis; FRAX; fracture; fall; pain; quality of life.
- Open Access
- 30 June 2022
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 12 (2) , 46-51
Anti-osteoporotic treatment and COVID-19 risk: is there an association?
Introduction. Despite the recent ASBMR, AACE, Endocrine Society, ECTS&NOF guidelines for osteoporosis management in the era of COVID-19 the impact of antiosteoporotic drugs on disease risk and severity is insufficiently studied. The purpose of this study was to assess the COVID-19 risk for the patients receiving the parenteral bisphosphonate or Denosumab treatment, and the severity of its course in patients with systemic osteoporosis. Materials and methods. We performed the phone survey and studied the results of 195 patients (92 % women; mean age – 62.7±10.8 years) with systemic osteoporosis depending on the current use of parenteral antiresorptive drugs (Zoledronic, Ibandronic acids, or Denosumab, n = 125) and compared the results with data of the patients with osteoporosis who did not use any anti-osteoporotic drugs previously (n = 70). Results. The group of patients with COVID-19 included 32.9 % of patients who did not receive previously any anti-osteoporotic treatment and 33.3 % of osteoporotic patients treated with parenteral antiresorptive drugs. The share of the patients taking the Zoledronic acid who fell ill with COVID-19 was 29.2 %, the share of those taking the Ibandronic acid was 34.4%, and the share of those taking Denosumab was 42.9 %. We did not reveal any significant differences in the COVID-19 frequency and severity depending on the presence and type of parenteral anti-osteoporotic therapy. Additionally, there were no differences depending on the patients' age, gender, obesity, and other osteoporosis risk factors. The risk of COVID-19 in the patients with systemic osteoporosis did not differ depending on antiresorptive drug use, amounting (odds ratio (OR) 95 % CI) 1.1 (0.6-2.0), or on the use of the definite anti-osteoporotic drug (for the Zoledronic acid – 0.9 (0.4-2.0), the Ibandronic acid – 1.1 (0.5-2.3), and for the Denosumab – 1.6 (0.5-5.2). Conclusions. Parenteral anti-osteoporotic drugs (Zoledronic acid, Ibandronic acid, or Denosumab) do not have any influence on COVID-19 frequency and severity and can be recommended for the continuation of the treatment of patients with osteoporosis.
- 30 June 2022
- Published by Publishing House Zaslavsky in PAIN, JOINTS, SPINE
- Vol. 12 (2) , 46-51
Open AccessAnti-osteoporotic treatment and COVID-19 risk: is there an association?
Introduction. Despite the recent ASBMR, AACE, Endocrine Society, ECTS&NOF guidelines for osteoporosis management in the era of COVID-19 the impact of antiosteoporotic drugs on disease risk and severity is insufficiently studied. The purpose of this study was to assess the COVID-19 risk for the patients receiving the parenteral bisphosphonate or Denosumab treatment, and the severity of its course in patients with systemic osteoporosis. Materials and methods. We performed the phone survey and studied the results of 195 patients (92 % women; mean age – 62.7±10.8 years) with systemic osteoporosis depending on the current use of parenteral antiresorptive drugs (Zoledronic, Ibandronic acids, or Denosumab, n = 125) and compared the results with data of the patients with osteoporosis who did not use any anti-osteoporotic drugs previously (n = 70). Results. The group of patients with COVID-19 included 32.9 % of patients who did not receive previously any anti-osteoporotic treatment and 33.3 % of osteoporotic patients treated with parenteral antiresorptive drugs. The share of the patients taking the Zoledronic acid who fell ill with COVID-19 was 29.2 %, the share of those taking the Ibandronic acid was 34.4%, and the share of those taking Denosumab was 42.9 %. We did not reveal any significant differences in the COVID-19 frequency and severity depending on the presence and type of parenteral anti-osteoporotic therapy. Additionally, there were no differences depending on the patients' age, gender, obesity, and other osteoporosis risk factors. The risk of COVID-19 in the patients with systemic osteoporosis did not differ depending on antiresorptive drug use, amounting (odds ratio (OR) 95 % CI) 1.1 (0.6-2.0), or on the use of the definite anti-osteoporotic drug (for the Zoledronic acid – 0.9 (0.4-2.0), the Ibandronic acid – 1.1 (0.5-2.3), and for the Denosumab – 1.6 (0.5-5.2). Conclusions. Parenteral anti-osteoporotic drugs (Zoledronic acid, Ibandronic acid, or Denosumab) do not have any influence on COVID-19 frequency and severity and can be recommended for the continuation of the treatment of patients with osteoporosis.
- Open Access
- 29 December 2021
- Published by Riset Publishing Services L.L.C. in PAIN, JOINTS, SPINE
- Vol. 11 (4) , 172-178
Comparative evaluation of the effectiveness of parenteral and oral forms of diclofenac sodium and meloxicam in patients with symptomatic osteoarthritis of the knee joints
Nonsteroidal anti-inflammatory drug are considered at the cornerstone drug therapy for osteoarthritis (OA) because their main function is to relieve pain and reduce inflammation. The aim of the study was to compare the efficacy of treatment of patients with symptomatic knee osteoarthritis (KOA) using the diclofenac sodium and meloxicam. Materials and methods. The study included 40 females aged 50–75 years with symptomatic KOA, and were divided into 2 groups: group I — 20 subjects receiving diclofenac sodium; group II — 20 subjects receiving meloxicam. The intensity of the pain syndrome and the functional of the knee were assessed using the WOMAC scale, the four-component VAS, the Lequesne index, and functional tests at each visit. The safety of medication was determined by the frequency adverse events. Results. Patients of two groups did not differ by age and initial level of knee pain. During the treatment, patients in both groups showed a reduction of pain intensity by VAS on 5 and 20 days of therapy (p < 0.01) without significant difference between groups, however in the subjects of group I the level of pain intensity by VAS on days 2 and 3 of treatment was significantly lower compared to group II (p = 0.003 and p = 0.03, respectively). In patients of both groups were revealed a significant reduction of pain, stiffness and physical function by WOMAC subscales on 5 and 20 days of treatment, but in group I the intensity of pain after 5 days of treatment was significantly lower (t = 2.8, p < 0.004) compared to group II. Conclusions. The treatment of patients with knee OA using the diclofenac sodium and meloxicam is effective, but in the case of diclofenac sodium analgesic effect were faster, already on 2 and 3 days of treatment were detected significantly lower pain intensity by VAS and on 5 days by WOMAC pain subscale.
- 29 December 2021
- Published by Riset Publishing Services L.L.C. in PAIN, JOINTS, SPINE
- Vol. 11 (4) , 172-178
Open AccessComparative evaluation of the effectiveness of parenteral and oral forms of diclofenac sodium and meloxicam in patients with symptomatic osteoarthritis of the knee joints
Nonsteroidal anti-inflammatory drug are considered at the cornerstone drug therapy for osteoarthritis (OA) because their main function is to relieve pain and reduce inflammation. The aim of the study was to compare the efficacy of treatment of patients with symptomatic knee osteoarthritis (KOA) using the diclofenac sodium and meloxicam. Materials and methods. The study included 40 females aged 50–75 years with symptomatic KOA, and were divided into 2 groups: group I — 20 subjects receiving diclofenac sodium; group II — 20 subjects receiving meloxicam. The intensity of the pain syndrome and the functional of the knee were assessed using the WOMAC scale, the four-component VAS, the Lequesne index, and functional tests at each visit. The safety of medication was determined by the frequency adverse events. Results. Patients of two groups did not differ by age and initial level of knee pain. During the treatment, patients in both groups showed a reduction of pain intensity by VAS on 5 and 20 days of therapy (p < 0.01) without significant difference between groups, however in the subjects of group I the level of pain intensity by VAS on days 2 and 3 of treatment was significantly lower compared to group II (p = 0.003 and p = 0.03, respectively). In patients of both groups were revealed a significant reduction of pain, stiffness and physical function by WOMAC subscales on 5 and 20 days of treatment, but in group I the intensity of pain after 5 days of treatment was significantly lower (t = 2.8, p < 0.004) compared to group II. Conclusions. The treatment of patients with knee OA using the diclofenac sodium and meloxicam is effective, but in the case of diclofenac sodium analgesic effect were faster, already on 2 and 3 days of treatment were detected significantly lower pain intensity by VAS and on 5 days by WOMAC pain subscale.
- Open Access
- 25 October 2021
- Published by Orthopaedica, Traumatology, and Prosthetics in ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS
- No. 3,p. 101-106
Sarcopenia, sarcopenic obesity and osteoarthritis
Sarcopenia is considered an important geriatric syndrome, the manifestations of which lead to impaired quality of life and increased mortality. Sarcopenia is a disease associated with decreased muscle mass and strength. Sarcopenic obesity is manifested by an increase in subcutaneous or visceral fat, fatty degeneration of muscles, and is also accompanied by impaired muscle function. After the age of 40, an average of 8 % loss of muscle mass is noted, and by the age of 80 this value can reach 50 %. The review examined the relationship between sarcopenia, sarcopenic obesity, and osteoarthritis (OA).Many exogenous and endogenous factors influence the development and course of OA. Based on the study of mechanisms of cellular and molecular profiles, the specific features for these frequently coexisting pathologies have been identified. The review presents the molecular mechanisms in the development of sarcopenia, sarcopenic obesity and osteoarthritis. Increased fat mass is manifested by increased adipogenesis, expression of inflammatory molecules (leptin, adiponectin, interleukin-1 (IL-1), IL-1b, IL-6 and tumor necrosis factor α) that contribute to chronic low-grade systemic inflammationand negatively affect muscle and joint quality. The relationship between elevated levels of myostatin and muscle weakness as well as myostatin accumulation in synovial fluid and severity of osteoarthritis was considered. Some common mechanisms in the development of sarcopenia and OA were noted: the influence of oxidative stress, systemic chronic inflammation, and disruption of the signaling pathway of bone morphogenetic proteins. Based on the analysis of associations between sarcopenia, sarcopenic obesity, and OA, population-based studies have revealed a high prevalence of knee OA with an increased risk among men with sarcopenic obesity. Women with sarcopenia and sarcopenic obesity had a high risk of knee OA in both groups. The review reviewed the prevention and treatment of the combined pathology, in particular the effect of sarcopenia on the results of total joint а rthroplasty in patients with OA. In general, sarcopenia, sarcopenic obesity, and OA can be considered as concomitant age-associated diseases that jointly affect quality of life and life expectancy.
- 25 October 2021
- Published by Orthopaedica, Traumatology, and Prosthetics in ORTHOPAEDICS TRAUMATOLOGY and PROSTHETICS
- No. 3,p. 101-106
Open AccessSarcopenia, sarcopenic obesity and osteoarthritis
Sarcopenia is considered an important geriatric syndrome, the manifestations of which lead to impaired quality of life and increased mortality. Sarcopenia is a disease associated with decreased muscle mass and strength. Sarcopenic obesity is manifested by an increase in subcutaneous or visceral fat, fatty degeneration of muscles, and is also accompanied by impaired muscle function. After the age of 40, an average of 8 % loss of muscle mass is noted, and by the age of 80 this value can reach 50 %. The review examined the relationship between sarcopenia, sarcopenic obesity, and osteoarthritis (OA).Many exogenous and endogenous factors influence the development and course of OA. Based on the study of mechanisms of cellular and molecular profiles, the specific features for these frequently coexisting pathologies have been identified. The review presents the molecular mechanisms in the development of sarcopenia, sarcopenic obesity and osteoarthritis. Increased fat mass is manifested by increased adipogenesis, expression of inflammatory molecules (leptin, adiponectin, interleukin-1 (IL-1), IL-1b, IL-6 and tumor necrosis factor α) that contribute to chronic low-grade systemic inflammationand negatively affect muscle and joint quality. The relationship between elevated levels of myostatin and muscle weakness as well as myostatin accumulation in synovial fluid and severity of osteoarthritis was considered. Some common mechanisms in the development of sarcopenia and OA were noted: the influence of oxidative stress, systemic chronic inflammation, and disruption of the signaling pathway of bone morphogenetic proteins. Based on the analysis of associations between sarcopenia, sarcopenic obesity, and OA, population-based studies have revealed a high prevalence of knee OA with an increased risk among men with sarcopenic obesity. Women with sarcopenia and sarcopenic obesity had a high risk of knee OA in both groups. The review reviewed the prevention and treatment of the combined pathology, in particular the effect of sarcopenia on the results of total joint а rthroplasty in patients with OA. In general, sarcopenia, sarcopenic obesity, and OA can be considered as concomitant age-associated diseases that jointly affect quality of life and life expectancy.
- Open Access
- 30 June 2021
- Published by Riset Publishing Services L.L.C. in PAIN, JOINTS, SPINE
- Vol. 11 (2) , 62-69
Age-related changes in bone tissue in men
The purpose of the study was to establish age-related changes of male bone tissue. Materials and methods. The study was conducted by the Department of Clinical Physiology and Pathology of the Musculoskeletal System of the State Institution “D.F. Chebotarev Institute of Gerontology by the National Academy of Medical Sciences of Ukraine”. It involved 342 healthy men aged 20 to 89 years without osteoporosis and osteoporotic fractures or any pathology with a confirmed impact on bone tissue, as well as any somatic pathology in the sub- and decompensation. The following methods of examination were used: questionnaire, anthropometric measurements, clinical and instrumental examination. Bone mineral density (BMD) was measured by the dual-energy X-ray absorptiometry machine “Prodigy, GEНС Lunar” at the level of the entire skeleton, lumbar spine (L1-L4), proximal femur and femoral neck, distal and ultra-distal forearm bones. Results. We have detected a significant 14.8 % decrease of BMD at the level of femoral neck in the group of men aged 60–69 years, by 20 % in the group of men aged 70–79 years, and by 24.1 % in the group of men aged 80–89 years compared to the men aged 20–29 years; at the same time, at the lumbar spine there was registered a decrease of this parameter by 1.6 % in men aged 60–69 years, by 1.9 % in men of 70–79 years and by 0.8 % in men of 80–89 years, respectively. Among the examined practically healthy men, the bone tissue remained at the normal level relative to age in 67.8 %; osteopenia was detected in 27.8 %, and osteoporosis in 4.4 %. Conclusions. An age-associated BMD reduction was registered at various skeletal sites in the practically healthy men without any clinically significant factors affecting bone tissue metabolism. The most pronounced BMD loss was observed at the level of femoral neck. At the same time, 4.4 % of examined had osteoporosis without any clinical signs.
- 30 June 2021
- Published by Riset Publishing Services L.L.C. in PAIN, JOINTS, SPINE
- Vol. 11 (2) , 62-69
Open AccessAge-related changes in bone tissue in men
The purpose of the study was to establish age-related changes of male bone tissue. Materials and methods. The study was conducted by the Department of Clinical Physiology and Pathology of the Musculoskeletal System of the State Institution “D.F. Chebotarev Institute of Gerontology by the National Academy of Medical Sciences of Ukraine”. It involved 342 healthy men aged 20 to 89 years without osteoporosis and osteoporotic fractures or any pathology with a confirmed impact on bone tissue, as well as any somatic pathology in the sub- and decompensation. The following methods of examination were used: questionnaire, anthropometric measurements, clinical and instrumental examination. Bone mineral density (BMD) was measured by the dual-energy X-ray absorptiometry machine “Prodigy, GEНС Lunar” at the level of the entire skeleton, lumbar spine (L1-L4), proximal femur and femoral neck, distal and ultra-distal forearm bones. Results. We have detected a significant 14.8 % decrease of BMD at the level of femoral neck in the group of men aged 60–69 years, by 20 % in the group of men aged 70–79 years, and by 24.1 % in the group of men aged 80–89 years compared to the men aged 20–29 years; at the same time, at the lumbar spine there was registered a decrease of this parameter by 1.6 % in men aged 60–69 years, by 1.9 % in men of 70–79 years and by 0.8 % in men of 80–89 years, respectively. Among the examined practically healthy men, the bone tissue remained at the normal level relative to age in 67.8 %; osteopenia was detected in 27.8 %, and osteoporosis in 4.4 %. Conclusions. An age-associated BMD reduction was registered at various skeletal sites in the practically healthy men without any clinically significant factors affecting bone tissue metabolism. The most pronounced BMD loss was observed at the level of femoral neck. At the same time, 4.4 % of examined had osteoporosis without any clinical signs.
- Open Access
- 10 June 2021
- Published by Hindawi Limited in Journal of Osteoporosis
- Vol. 2021, 1-7
FRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine
Objectives. Osteoporosis, in addition to its consequent fracture burden, is a common and costly condition. FRAX® is a well-established, validated, web-based tool which calculates the 10-year probability of fragility fractures. A FRAX model for Ukraine has been available since 2016 but its output has not yet been translated into intervention thresholds for the treatment of osteoporosis in Ukraine; we aimed to address this unmet need in this analysis. Methods. In a referral population sample of 3790 Ukrainian women, 10-year probabilities of major osteoporotic fracture (MOF) and hip fracture separately were calculated using the Ukrainian FRAX model, with and without femoral neck bone mineral density (BMD). We used a similar approach to that first proposed by the UK National Osteoporosis Guideline Group, whereby treatment is indicated if the probability equals or exceeds that of a woman of the same age with a prior fracture. Results. The MOF intervention threshold in females (the age-specific 10-year fracture probability) increased with age from 5.5 at the age of 40 years to 11 at the age of 75 years where it plateaued and then decreased slightly at age 90 (10). Lower and upper thresholds were also defined to determine the need for BMD, if not already measured; the approach targets BMD measurements to those at or near the intervention threshold. The proportion of the referral populations eligible for treatment, based on prior fracture or similar or greater probability, ranged from 44 to 69 depending on age. The prevalence of the previous fracture rose with age, as did the proportion eligible for treatment. In contrast, the requirement for BMD testing decreased with age. Conclusions. The present study describes the development and application of FRAX-based assessment guidelines in Ukraine. The thresholds can be used in the presence or absence of access to BMD and optimize the use of BMD where access is restricted.
- 10 June 2021
- Published by Hindawi Limited in Journal of Osteoporosis
- Vol. 2021, 1-7
Open AccessFRAX-Based Intervention Thresholds for Osteoporosis Treatment in Ukraine
Objectives. Osteoporosis, in addition to its consequent fracture burden, is a common and costly condition. FRAX® is a well-established, validated, web-based tool which calculates the 10-year probability of fragility fractures. A FRAX model for Ukraine has been available since 2016 but its output has not yet been translated into intervention thresholds for the treatment of osteoporosis in Ukraine; we aimed to address this unmet need in this analysis. Methods. In a referral population sample of 3790 Ukrainian women, 10-year probabilities of major osteoporotic fracture (MOF) and hip fracture separately were calculated using the Ukrainian FRAX model, with and without femoral neck bone mineral density (BMD). We used a similar approach to that first proposed by the UK National Osteoporosis Guideline Group, whereby treatment is indicated if the probability equals or exceeds that of a woman of the same age with a prior fracture. Results. The MOF intervention threshold in females (the age-specific 10-year fracture probability) increased with age from 5.5 at the age of 40 years to 11 at the age of 75 years where it plateaued and then decreased slightly at age 90 (10). Lower and upper thresholds were also defined to determine the need for BMD, if not already measured; the approach targets BMD measurements to those at or near the intervention threshold. The proportion of the referral populations eligible for treatment, based on prior fracture or similar or greater probability, ranged from 44 to 69 depending on age. The prevalence of the previous fracture rose with age, as did the proportion eligible for treatment. In contrast, the requirement for BMD testing decreased with age. Conclusions. The present study describes the development and application of FRAX-based assessment guidelines in Ukraine. The thresholds can be used in the presence or absence of access to BMD and optimize the use of BMD where access is restricted.
- Open Access
- 26 March 2021
- Published by Riset Publishing Services L.L.C. in PAIN, JOINTS, SPINE
- Vol. 11 (1) , 28-34
Эффективность и безопасность лечения препаратом Фастум® гель у лиц с болью в нижней части спины
Целью исследования было изучение эффективности и безопасности терапии препаратом Фастум® гель у лиц с болью в нижней части спины (БНЧС) на фоне дегенеративно-дистрофических изменений позвоночника. Материалы и методы. Обследованы 24 человека мужского и женского пола в возрасте 50–69 лет с БНЧС продолжительностью более 14 дней с последующим делением на две группы. Группа I — 12 пациентов, получавших кетопрофен в виде аппликаций тонким слоем на поясничную область 2 раза в сутки в течение 10 дней. Группа II — 12 пациентов, которым проводили аппликации вазелина тонким слоем на тот же участок 2 раза в сутки в течение 10 дней. Пациенты применяли исследуемые препараты в качестве монотерапии. Обследование проводили перед началом терапии и на 10-й и 20-й день лечения. Результаты. У пациентов, получавших аппликации кетопрофеном, достоверно снижалась интенсивность боли по четырем составляющим визуально-аналоговой шкалы и опроснику Роланда — Морриса. Вместе с этим достоверно улучшались функциональные возможности согласно результатам теста Шобера (t = 3,54, р = 0,005) и Томайера (t = 3,08, р = 0,01). По результатам шкалы EuroQul-5D показатели качества жизни у пациентов, применявших локальную форму кетопрофена, достоверно улучшились на 45 % (t = 4,19, р = 0,002), на 39,3 % согласно анкете Освестри через 10 суток лечения (t = 3,9, р = 0,002). 75 % пациентов основной группы и 33,3 % группы сравнения оценили эффективность лечения как высокую согласно индексу Ликерта. В обеих группах не было зарегистрировано ни одного локального и системного побочного эффекта. Выводы. Кетопрофен гель в виде монотерапии достоверно снижал интенсивность болевого синдрома и улучшал функциональные возможности больных с БНЧС. Отсутствие побочных эффектов при лечении препаратом свидетельствует о его высоком профиле безопасности для пациентов.
- 26 March 2021
- Published by Riset Publishing Services L.L.C. in PAIN, JOINTS, SPINE
- Vol. 11 (1) , 28-34
Open AccessЭффективность и безопасность лечения препаратом Фастум® гель у лиц с болью в нижней части спины
Целью исследования было изучение эффективности и безопасности терапии препаратом Фастум® гель у лиц с болью в нижней части спины (БНЧС) на фоне дегенеративно-дистрофических изменений позвоночника. Материалы и методы. Обследованы 24 человека мужского и женского пола в возрасте 50–69 лет с БНЧС продолжительностью более 14 дней с последующим делением на две группы. Группа I — 12 пациентов, получавших кетопрофен в виде аппликаций тонким слоем на поясничную область 2 раза в сутки в течение 10 дней. Группа II — 12 пациентов, которым проводили аппликации вазелина тонким слоем на тот же участок 2 раза в сутки в течение 10 дней. Пациенты применяли исследуемые препараты в качестве монотерапии. Обследование проводили перед началом терапии и на 10-й и 20-й день лечения. Результаты. У пациентов, получавших аппликации кетопрофеном, достоверно снижалась интенсивность боли по четырем составляющим визуально-аналоговой шкалы и опроснику Роланда — Морриса. Вместе с этим достоверно улучшались функциональные возможности согласно результатам теста Шобера (t = 3,54, р = 0,005) и Томайера (t = 3,08, р = 0,01). По результатам шкалы EuroQul-5D показатели качества жизни у пациентов, применявших локальную форму кетопрофена, достоверно улучшились на 45 % (t = 4,19, р = 0,002), на 39,3 % согласно анкете Освестри через 10 суток лечения (t = 3,9, р = 0,002). 75 % пациентов основной группы и 33,3 % группы сравнения оценили эффективность лечения как высокую согласно индексу Ликерта. В обеих группах не было зарегистрировано ни одного локального и системного побочного эффекта. Выводы. Кетопрофен гель в виде монотерапии достоверно снижал интенсивность болевого синдрома и улучшал функциональные возможности больных с БНЧС. Отсутствие побочных эффектов при лечении препаратом свидетельствует о его высоком профиле безопасности для пациентов.